These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8228934)

  • 41. [Evaluation of serological status of children following hepatitis B vaccination during infancy].
    Süleyman A; Gökçay G; Badur S; Aykın S; Kılıç G; Tamay Z; Unüvar E; Güler N
    Mikrobiyol Bul; 2012 Jan; 46(1):47-56. PubMed ID: 22399171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule.
    Chen CC; Chang MH; Lee HC; Twu SJ; Safary A
    Acta Paediatr Taiwan; 1999; 40(3):157-60. PubMed ID: 10910606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to a booster dose 18 months after a low anti-HBs response (10-99 IU/l) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.
    Struve J; Aronsson B; Frenning B; Forsgren M; Weiland O
    Infection; 1995; 23(1):42-5. PubMed ID: 7744490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age.
    Greenberg DP; Vadheim CM; Wong VK; Marcy SM; Partridge S; Greene T; Chiu CY; Margolis HS; Ward JI
    Pediatr Infect Dis J; 1996 Jul; 15(7):590-6. PubMed ID: 8823852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers.
    Belloni C; Orsolini P; Martinetti M; Chirico G; Cerbo RM; Comolli G; Maccarini U; Barlassina C; Togni C; Polatti F
    New Microbiol; 1993 Jul; 16(3):237-44. PubMed ID: 8366819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.
    Wang ZZ; Gao YH; Lu W; Jin CD; Zeng Y; Yan L; Ding F; Li T; Liu XE; Zhuang H
    Hum Vaccin Immunother; 2017 Apr; 13(4):909-915. PubMed ID: 27874311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.
    Rey D; Piroth L; Wendling MJ; Miailhes P; Michel ML; Dufour C; Haour G; Sogni P; Rohel A; Ajana F; Billaud E; Molina JM; Launay O; Carrat F;
    Lancet Infect Dis; 2015 Nov; 15(11):1283-91. PubMed ID: 26257021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis B vaccine booster dose: low-dose recombinant hepatitis B vaccines as a booster dose.
    Bryan JP; MacArthy P; Rudock A; Fogarty JP; Dowd H; Legters LJ; Perine PL
    Am J Infect Control; 1997 Jun; 25(3):215-22. PubMed ID: 9202817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparison on the antibody response after primary immunization of 5 µg and 10 µg hepatitis B vaccine made by recombinant DNA techniques among newborns].
    Zhang L; Zhang W; Zhai XJ; Li YP; Li J; Yan BY; Li YT; Zhu FC; Huang T; Li LQ; Gong XH; Cui FQ; Liang XF; Xu AQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Mar; 33(3):305-8. PubMed ID: 22613384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children.
    el-Sawy IH; Mohamed ON
    East Mediterr Health J; 1999 Sep; 5(5):922-32. PubMed ID: 10983531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation.
    Duca P; Del Pont JM; D'Agostino D
    J Pediatr Gastroenterol Nutr; 2001 Feb; 32(2):168-70. PubMed ID: 11321387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. The Kaiser-UCLA Vaccine Study Group.
    Greenberg DP; Vadheim CM; Marcy SM; Partridge S; Jing J; Chiu CY; Greene T; Margolis HS; Ward JI
    Vaccine; 1996 Jun; 14(8):811-6. PubMed ID: 8817829
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination.
    Baldy JL; de Lima GZ; Morimoto HK; Reiche EM; Matsuo T; de Mattos ED; Sudan LC
    Rev Inst Med Trop Sao Paulo; 2004; 46(2):103-7. PubMed ID: 15141282
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intradermal vaccination of adults with three low doses (2 micrograms) of recombinant hepatitis B vaccine. I. Seroconversion rate and adverse effects.
    Baldy JL; Elisbão Mdo C; Anzai ET; Pontello R; Reiche EM; Zaha-Inouye MM; Matsuo T; Tonani PC; Ferelle A; Henriques JN; Neves J
    Mem Inst Oswaldo Cruz; 2003 Dec; 98(8):1101-7. PubMed ID: 15049098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination.
    Zhao YL; Han BH; Zhang XJ; Pan LL; Zhou HS; Gao Z; Hao ZY; Wu ZW; Ma TL; Wang F; Li Q; Bi SL; Ma JC
    BMC Infect Dis; 2019 May; 19(1):482. PubMed ID: 31146699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders.
    Goldwater PN
    Vaccine; 1997 Mar; 15(4):353-6. PubMed ID: 9141204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The persistence of anti-hepatitis B surface antibodies to three years of age: is a hepatitis B vaccine booster required?
    Gunn TR; Woodfield DG
    N Z Med J; 1993 Nov; 106(968):499-501. PubMed ID: 8247433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: a multicentre, open-label, randomised, controlled, superiority trial.
    Raven SFH; Hoebe CJPA; Vossen ACTM; Visser LG; Hautvast JLA; Roukens AHE; van Steenbergen JE
    Lancet Infect Dis; 2020 Jan; 20(1):92-101. PubMed ID: 31629649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results.
    Van Herck K; Van Damme P; Thoelen S; Meheus A
    Vaccine; 1998 Dec; 16(20):1933-5. PubMed ID: 9796046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.